IGIT2/26: Immunopathology of GIT

This EQA round of the accredited programme was carried out according to the document ***EQA Plan 2026***.
Typing conventions: *We are using comma as a decimal separator and dates in day.month.year format.*

Samples

The samples were prepared by the subcontractor.
3 sets of samples were used in the round, with each set containing 2 samples labelled Ax and Bx (where x is the set number). Each participant received the sets according to their order.

Assigned values

The assigned values are determined by a consensus of the participants. In the case of qualitative results, the consensus is reached if at least 80 % of the participants agree on the result.

Supervisor's comment

There were 89 participants in this round of which 1 from Austria and 20 from Slovakia.

Consensus and a high success rate were achieved for all tests, with the exception of **anti-Saccharomyces cerevisiae IgG** in sample B3. Sample B3 was prepared as a pool of 10 blood donor samples intended for the transfusion service. It was also repeatedly tested as part of an ongoing stability study, consistently yielding negative results. During the testing conducted for the preparation of this sample, a value of 4,8 kU/L was measured (cut-off = 18 kU/L). We therefore expected a *negative* result, which was indeed reported by 74 % of the participants. The remaining quarter reported *positive* or *inconclusive* results. As shown in the statistics available on the website, these *positive/inconclusive* results were reported by users of a wide variety of test kits. There is no indication that the issue lies with any specific kit; rather, it appears that the antibody concentration was close to the cut-off value.

Long-term success rate

You can find the overview of the total success of the participants of this round over last 2 years in the following table. Particular ranges of success are defined in the column headers (percentage of the tests on which the participant reported the correct result). Next 2 lines contain both absolute and relative number of participants who reached the success from the header**.**

Success		***0 %***	***1 - 74 %***	***75 - 79 %***	***80 - 89 %***	***90 - 94 %***	***95 - 99 %***	***100 %***
Success in words		unsatisfactory		acceptable	good	very good	excellent	
Count	absolute	0	1	0	2	0	3	83
	relative	-	1,1 %	-	2,2 %	-	3,4 %	93 %
Note: You can find your individual success over last 2 years in your result sheet.								

Overall success of most participants of this round over the last 2 years is 95 % or higher.
Success rates below 95 % should be considered to be an impulse to improve.

Scientific supervision: prof. RNDr. Ctirad Andrýs, Ph.D.
ÚKIA FN
Hradec Králové
e-mail: ctirad.andrys@fnhk.cz

Supplements

As a supplement to this report, each participant who submitted the results gains:

Name	***Description***
Confirmation of attendance Result sheet	The conditions for issuing the relevant document specified in the EQA Plan must be met.

The supplements are identified by their name, EQA round identification and participant code and are intended for the needs of the participant.
If you reported the results in this round, you can find your individual evaluation (reports) in the **Cibule** application (https://www.eqa.cz/cibule). After login, select ***EQA Results - View*** in the menu and then click the ***Reports*** button for the particular round.

Additional information

The final report, with the exception of the supplements, is public. Further information is freely available to the participants and other professionals at www.sekk.cz, in particular:

- The summary of the results of this round, including this final report.
- The document ***EQA Plan*** (contains information that applies both to this round and also the EQA in general).
- Explanation of the content of the particular supplements mentioned above.

IGIT2/26: Immunopathology of GIT

- Contact to the EQA provider and the EQA coordinator and the list of all supervisors, including contacts.